Ozempic and Wegovy for children — what applies?

What are GLP-1 medications?

GLP-1 (glucagon-like peptide-1) is a hormone that the body releases naturally after a meal. It lowers blood sugar, slows gastric emptying, and increases feelings of satiety. GLP-1 medications are synthetic analogues of this hormone and have been shown to significantly reduce appetite and body weight.

The most common GLP-1 medications:

• Ozempic (semaglutide) — approved for type 2 diabetes in adults. Not approved for weight management, neither in adults nor children.
• Wegovy (semaglutide) — the same active substance as Ozempic, but at a higher dose and approved for weight management. Approved for children from 12 years of age with obesity.
• Saxenda (liraglutide) — approved for weight management in adults and adolescents from 12 years of age with obesity.

There are also newer medications such as tirzepatide (Mounjaro/Zepbound), but they are not yet approved for children in Europe.

When can a child receive Wegovy or Saxenda?

Approval does not mean that the medications can be prescribed freely. In Sweden, according to the national care programme, the following practice applies:

• The child must have obesity (iso-BMI ≥ 30) and be at least 12 years old for semaglutide or liraglutide.
• Combined lifestyle treatment must first have been trialled in a structured manner for an adequate period.
• Pharmacological treatment is initiated and monitored within specialist care (BUMM (paediatric outpatient clinic) or Rikscentrum Barnobesitas (National Centre for Childhood Obesity)).
• Treatment is evaluated regularly against clear goals and criteria for continuation.

It is never a fast track or a shortcut. The medications are a tool within a broader treatment programme, not a standalone solution.

What is Ozempic — and why not for children?

Ozempic is semaglutide at a dosage approved for the treatment of type 2 diabetes in adults. The medication is not approved for:

• Weight management (for this, Wegovy is used, which has the same active substance but a different dosage).
• Children in any age group.
• Type 2 diabetes in children (other diabetes medications are used for this).

Despite this, Ozempic has been the subject of widespread public discussion regarding weight loss. That discussion concerns adults using the medication "off-label" — that is, outside its approved indication. For children, this is not an option in Swedish healthcare.

Are these medications covered by the pharmaceutical benefits scheme?

No — neither Wegovy nor Saxenda is currently covered by the pharmaceutical benefits scheme for the treatment of obesity. This means the patient (or family) pays the entire cost themselves, which is a substantial amount — thousands of Swedish kronor per month. This is an active debate in Swedish healthcare, and TLV (the Dental and Pharmaceutical Benefits Agency) has not granted reimbursement for these medications.

For children with concurrent type 2 diabetes or other conditions, the situation may differ. Insurance companies may cover the treatment in certain cases, but this varies individually.

Side effects and risks in children

GLP-1 medications have a side-effect profile that is well documented in adults. In children, experience is more limited, but the most common side effects are similar to those in adults:

• Gastrointestinal symptoms — nausea, vomiting, diarrhoea, constipation. These are most common initially and usually ease as the body adapts.
• Reduced appetite — an intended effect, but must be monitored to ensure adequate nutritional intake.
• Fatigue, headache.
• Gallbladder issues have been reported in rare cases.

Because children are still growing, rigorous monitoring of growth, nutritional intake, and psychological well-being is required. This is one of several reasons why treatment takes place exclusively within specialist care.

What does treatment look like in practice?

A typical treatment pathway in Sweden when medication becomes relevant:

1. Assessment of indication. A specialist physician assesses whether the child meets the criteria.
2. Information and consent. The child and guardians are informed about what the treatment involves, what effects can be expected, possible side effects, and what it costs.
3. Dose escalation. The dose is titrated up gradually over several weeks to minimise side effects.
4. Follow-up. Regular follow-up appointments with measurement of weight, height, blood pressure, blood tests, and discussions about well-being.
5. Evaluation. After a few months, an assessment is made to determine whether the treatment is providing the expected effect. If not, it is discontinued.

In parallel, lifestyle treatment, which is a multi-year process, continues throughout. The medication does not replace the work on diet, physical activity, and daily routines — it supports it.

Why not "just" have the child diet?

Obesity is a chronic disease with a strong biological component. When someone with a genetic predisposition to obesity reduces their food intake, the body lowers its metabolic rate and increases hunger signals — these are built-in protective mechanisms that make sustained weight loss difficult. Many children and adolescents who "diet" regain the weight, often more than they lost. This is one reason why medications can be appropriate in severe cases: they target the very biological mechanisms that make weight loss so difficult.

At the same time, medication is not the right approach for everyone, and for many children, combined lifestyle treatment goes a long way. The assessment is made on an individual basis.

Summary

• Ozempic: not approved for weight management, not approved for children.
• Wegovy: approved for weight management from age 12 in obesity.
• Saxenda: approved from age 12 in obesity.
• Decisions are made within specialist care, not at a vårdcentral (primary care centre) or online.
• Lifestyle treatment first, medication as an adjunct if response is insufficient.
• No reimbursement — the family pays the full cost.

Related questions

• When is overweight in children something to take seriously?The patterns that signal overweight needs investigation — and where to seek help.
• Is obesity hereditary?The heritability of BMI is 40–70%. But genes do not decide alone — here is how the family can influence the risk.
• What is overweight for a 10-year-old?BMI thresholds for a 10-year-old explained — why iso-BMI is not the same as the adult scale.

See all questions and answers →